Acumen Pharmaceuticals to Present Key Findings from ALTITUDE-AD Trial at CTAD Conference
News related to:Acumen Pharmaceuticals, Inc · 1 min read
NEWTON, Mass., Oct. 22, 2026 /CourierPR/ -- Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, will present key findings from its Phase 2 ALTITUDE-AD trial at the upcoming 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, set to take place from November 16 to 19, 2026, both in-person and online.
The presentations will focus on preliminary baseline characteristics of study participants, their treatment expectations and motivations, and the care experiences of their partners. These insights are crucial for understanding the biology of early Alzheimer’s disease and the full experience of those living with it.
Acumen’s Chief Medical Officer, Dr. Eric Siemers, emphasized the importance of these presentations.
This session will take place on Monday, November 16, from 2:00 p.m. to 5:30 p.m. Eastern Standard Time (EST).
This session will also be held on Monday, November 16, from 2:00 p.m. to 5:30 p.m. EST.
This session will take place on the same day and time.
The ALTITUDE-AD trial, initiated in 2024, is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline compared to placebo in participants with early Alzheimer’s disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union, and the United Kingdom. Topline results are expected in late 2026.
Sabirnetug (ACU193) is a humanized monoclonal antibody discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function, and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease.